disclosure - i speaker bureau – sanofi aventis bristol myers squibb daichi sankyo/lilly
DESCRIPTION
Results of CRYSTAL AMI: A Pilot Trial Before INFUSE AMI, the Concept and Evolution in Thrombus Management . Saihari Sadanandan, MD, FACC, FASE, Dip. CBNC, FSCAI Associate Professor of Clinical Medicine Director, Vascular Interventions Division of Cardiology - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/1.jpg)
Results of CRYSTAL AMI: A Pilot Trial Before INFUSE AMI, the Concept and Evolution in Thrombus Management
Saihari Sadanandan, MD, FACC, FASE, Dip. CBNC, FSCAIAssociate Professor of Clinical Medicine
Director, Vascular InterventionsDivision of Cardiology
IU- HealthIndiana University
Indianapolis
![Page 2: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/2.jpg)
Disclosure - ISpeaker Bureau – Sanofi Aventis
Bristol Myers SquibbDaichi Sankyo/Lilly
Educational Grant from Atrium Medicaltowards IRB fees to collect data on the case Studies
CRYSTAL – AMI slide courtesy – R. Dave, MD
![Page 3: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/3.jpg)
Acute Inferior MI: Primary PCI for STEMI
![Page 4: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/4.jpg)
Primary PCI for STEMI: Predilation and Stent
![Page 5: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/5.jpg)
Distal Embolization during primary PCI for STEMI
![Page 6: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/6.jpg)
5 year outcomes of No-reflow during Primary PCI for STEMI
• N = 1406
• Pts with STEMI undergoing PCI
• No reflow defined as TIMI <3 flow or TMPG 0-1 after successful PCI
• Occurred in 30% of pts
• 7-14 day infarct size 15% vs. 8% p<0.001
• 5-year mortality 18.2% vs. 9.5%, p < 0.001
Ndrepepa G, et al.. J Am Coll Cardiol. 2010;55:2383-2389.
![Page 7: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/7.jpg)
Distal embolization and small distal vessel cutoff is neither infrequent norbenign!!!!
• Occurs in about 15% of patients undergoing PCI for STEMI
• Associated with larger infarct size, lower LVEF and increased long term Mortality
(Eur H J 2002:23-1112-17
![Page 8: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/8.jpg)
(Eur H J 2002:23-1112-17
N=178 No DE n = 151 (85%)
DE n = 27 (15%) P Value
LVEF (%) 51 ± 9 42 ± 14 0.005
Cardiac enzyme 847 ± 631 1612 ± 1008 0.001
Mortality 15 (9%) 12 (44%) < 0.001
(Eur H J 2002:23-1112-17)
Distal embolization during Primary PCI for STEMI
![Page 9: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/9.jpg)
IMPACT OF MYOCARDIAL BLUSH GRADE
![Page 10: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/10.jpg)
0
2
4
6
8
Mor
t alit
y (%
) 6.2%
4.4%
2.0%
n=203 n=46 n=434
TMP Grade 3
P=0.05
n=79
5.1%
Normal ground-glassappearance of blush.Dye mildly persistent
at end of washout.
Dye strongly persistentat end of washout.
Gone by next injection.
Stain present.Blush persists
on next injection.
No or minimal blush.TMP Grade 2 TMP Grade 1 TMP Grade 0
Adapted from Gibson CM, et al. Circulation. 2000;101:125-130.
TIMI Myocardial Perfusion (TMP) Grades
![Page 11: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/11.jpg)
80
85
90
953
2
0/1
100C
umul
ativ
e S
urvi
val (
%)
0 2 4 6 8 10 1275
Final Blush Score (patients with final TIMI 3 flow)
Blush 1-Year Mortality32
0/1
6.8%13.2%18.3%
P=0.004
Myocardial Perfusion After Primary PCI is the Strongest Predictor of Mortality independently from IRA reopening
![Page 12: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/12.jpg)
No reflow/ slow flow Poor TIMI flow
Poor MBG Larger Infarct size
Thrombus
Effects of Thrombo embolization during Primary PCI
![Page 13: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/13.jpg)
2.7
5.3
3.1
4.4
2.83.4
0
2
4
6
Adjunctive device prior to PCI PCI alone
Meta-Analysis of Various Devices—Mortality
Bavry AA, Kumbhani D, Bhatt DL. Eur Heart J. 2008;29:2989-3001.
Mechanical thrombectomy
Catheter thrombus aspiration
Embolic protection
P = 0.018
P = 0.050
P = 0.69
Mor
talit
y, %
![Page 14: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/14.jpg)
FZ 2008-12
TAPAS one year outcome: Myocardial blush grade and death
Death/reinfarction P= 0.001
Svilaas T et al. NEJM 2008;358-557 - FZ 2008-9 Myocardial blush grade
![Page 15: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/15.jpg)
Burzotta et al. European Heart Journal (2009) 30, 2193-2203
![Page 16: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/16.jpg)
Thrombectomy ± IIb/IIIa inhibitors7.4%
5.0% 4.8%
3.3%
IIb/IIIa inhib -Thrombectomy -
IIb/IIIa inhib +Thrombectomy -
IIb/IIIa inhib –Thrombectomy +
IIb/IIIa inhib +Thrombectomy +
4%
2%
8%
6%
MORTALITYP=0.02
![Page 17: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/17.jpg)
Summary of Current Limitations in STEMI PCI
• No optimal method of thrombus management• Once embolization occurs in primary PCI , it is a
challenging scenario• Higher MACE, Infarct size with poor MBG• Aspiration catheters are good, but not uniformly
effective.• There may be a synergistic effect between
thrombectomy and GP-IIBIIIA receptor inhibitors
![Page 18: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/18.jpg)
HOW CAN WE IMPROVE ON THIS FURTHER IN STEMI PCI?
COMBINE THE MECHANICAL APPROACH WITH PHARMACOLOGY -(INTRACORONARY DRUG)
MINIMIZE BLEEDING & MAXIMIZE DETHROMBOSIS
![Page 19: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/19.jpg)
Meta Analysis of IC Versus IV Abciximab administration of peer reviewed studies (N=2,301) 997 STEMI, 1304 NSTEMI
Hansen et al. Journal of Invasive Cardiology Vol 22; 6. June 2010. 278-282.
![Page 20: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/20.jpg)
Clearway Catheter and Intracoronary Abciximab
![Page 21: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/21.jpg)
Localized Drug Delivery via ClearWay for Pharmacological Thrombectomy and Prevention of Distal Embolization
![Page 22: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/22.jpg)
Occlusion
Containment
Infusion
During inflation, drug is being infused through the microporous balloon pores while blood flow is occluded, maximizing drug availability without substantial dilution by the systemic circulation.
Containment of the treatment zone provides extended residence time to help local drug bioavailability, concentration and dose
Controlled infusion at 1-4 ATM throughout the entire length of the targeted treatment zone provides increased residence time and uptake
![Page 23: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/23.jpg)
IC vs. Clearway Abciximab: The Coctail Study
Tamburino, Capodanno, et al. J Cardiovasc Med 2009
![Page 24: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/24.jpg)
Pre ReoPro through ClearWay
Post ReoPro through Clearway
![Page 25: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/25.jpg)
Coctail study: Change in Thrombus score
37.9
4.25
0
5
10
15
20
25
30
35
40
ClearWay Inf. Guid. Cath. Inf.
P=0.002
N= 20 N =21
Tamburino, Capodanno, et al. J Cardiovasc Med 2009
![Page 26: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/26.jpg)
Coctail study: Final TIMI MBG
2.78
2.56
2.452.5
2.552.6
2.652.7
2.752.8
ClearWay Inf. Guid. Cath. Inf.
ClearWay Inf.Guid. Cath. Inf.
P=0.24
N 20N 21Tamburino, Capodanno, et al. J Cardiovasc Med 2009
![Page 27: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/27.jpg)
CRYSTAL AMI: Study DesignSingle center, prospectively randomized
IV Abciximab ClearWay™ IC Abciximab
R 1:1
PCI as per standard of care, EvaluateMBG, TIMI flow, ST Resolution, LV Function at Discharge
30 day follow up, Echo, Resting Sestamibi
STEMI within 6 hours, Heparin, 600mg Clopidogrel (n=50)
![Page 28: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/28.jpg)
CRYSTAL- AMI: Demographics (N=48)Treatment arm IC =25 IV=23
Male/Female M=23, F=2 M=18, F=5Age 62 + 25 65 + 23HTN 14 14Angina 5 2CHF 1 0Prior PCI 6 2CABG 3 1DM 8 6Lipids 14 9Smoking C=9, F=2 C=6, F=0
![Page 29: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/29.jpg)
Manual/Mechanical Extraction catheter use (discretion of operator)
16
12
2 2
7
9
0
2
4
6
8
10
12
14
16
18
IC IV
ManualAngiojetNone
(n = 25) (n = 23)
![Page 30: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/30.jpg)
TIMI Flow Comparison (N=48)
16
1
17
3 1
5
2
4
1
24
3
19
IC TIMI Pre IC TIMI Post IV TIMI Pre IV TIMI Post
3
2
1
0
82%
(n = 25) (n = 23)
TIMI Flow96%
![Page 31: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/31.jpg)
Primary Endpoint: TIMI Myocardial Blush Grade (MBG) >2 (N=48)
17
1
18
72
3
1
5
2
8
0
18
1
12
IC Blush Pre IC Blush Post IV Blush Pre IV Blush Post
3
2
1
0
92%86%
1
(n = 25) (n = 23)
MBG
92% of IC versus 86% of IV patients
![Page 32: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/32.jpg)
MBG 3 and ST Resolution Rates comparison
18
12
21
18
IC Abciximab IV Abciximab
MBG 3ST Resolution
• In Tapas, MBG 3 was only achieved in 45% of patients in extraction arm (identical to IV Abciximab group), but was directly linked to 5 times increase in mortality. IC Abciximab Administration through ClearWay™ has resulted in 72% of patients leaving the lab with a blush score of 3.
(n = 25) (n = 23)
72%
80%
52%
70%
![Page 33: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/33.jpg)
Clinical Outcomes (N=48)
IC IVReadmissions 0 2
Death 0 1
![Page 34: Disclosure - I Speaker Bureau – Sanofi Aventis Bristol Myers Squibb Daichi Sankyo/Lilly](https://reader036.vdocument.in/reader036/viewer/2022081507/56815cca550346895dcad48f/html5/thumbnails/34.jpg)
Conclusions• Our understanding of evaluation of surrogate markers which directly
correlates to Mortality and Myocardial preservation has improved significantly
• Improving myocardial preservation also has profound economic impacts: low cost of care, better QOL, less need for ICD
• Localized superselective drug delivery (GP 2b3a inhibitors and vasodilators) with ClearWay as a stand alone device or when combined with Aspiration devices significantly improves MBG
• Series of data already promising, INFUSE AMI is underway…